Zymeworks Stock Price, News & Analysis

Zymeworks (Nasdaq: ZYME) announced management will attend two investor conferences in Miami in early December 2025.

Management will take part in one-on-one meetings and a fireside chat at the Evercore 8th Annual Healthcare Conference on Dec 2, 2025 at 10:00 AM ET, and at the Citi 2025 Global Healthcare Conference on Dec 3, 2025 at 3:15 PM ET.

Zymeworks (Nasdaq: ZYME) appointed Scott Platshon as Acting Chief Investment Officer effective Nov 18, 2025. Platshon will report to CEO Kenneth Galbraith and manage expected future cash flows from Ziihera (zanidatamab-hrii) and other licensed assets, and lead the operational execution of the company’s healthcare asset aggregation strategy.

Platshon stepped down from Zymeworks' board and will serve part-time while continuing as a Partner at EcoR1 Capital. The role focuses on converting royalty and asset cash flows into a diversified, revenue-generating portfolio to support long-term shareholder returns.

Zymeworks (NASDAQ: ZYME) announced a strategic initiative to optimize value from licensed products by building a diversified portfolio of revenue-generating healthcare assets while retaining in-house R&D capabilities.

Key elements: potential near-term Ziihera GEA regulatory milestones of $440.0M, pasritamig milestones of $434.0M plus royalties, a new $125.0M share repurchase authorization, and reported cash, cash equivalents and investments of $299.4M as of Sept 30, 2025.

Zymeworks (Nasdaq: ZYME) reported positive topline Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).

Key findings: Ziihera plus chemotherapy showed a clinically meaningful, statistically significant improvement in PFS versus trastuzumab plus chemotherapy and a clinically meaningful effect with a strong trend toward significance for OS at the first interim; Ziihera+Tevimbra (tislelizumab)+chemotherapy showed statistically significant improvements in OS and PFS. Safety was consistent with known profiles and no new signals were observed.

Next steps: Jazz plans a supplemental BLA submission in 1H 2026 and will present data in Q1 2026.

Zymeworks (NASDAQ: ZYME) reported 3Q-2025 results and a corporate update on Nov 6, 2025. Key highlights: revenue $27.6M (up from $16.0M in 3Q-2024) including a $25.0M J&J milestone and $1.0M royalties; net loss $19.6M vs $29.9M year-ago; cash resources $299.4M as of Sept 30, 2025 with projected runway into 2H-2027 when combined with anticipated regulatory milestones.

Clinical progress: encouraging Phase 1 ZW191 data presented (ORR 53% overall, 64% in gynecological cancers at 6.4–9.6 mg/kg); dose-optimization in ovarian cancer expected to start in 4Q-2025; first patient dosed in ZW251 Phase 1 for hepatocellular carcinoma. Completed $22.7M of share repurchases to Nov 4, 2025.

Zymeworks (Nasdaq: ZYME) announced that management will participate in investor conferences in November 2025. Key appearances include one-on-one meetings at the Stifel Healthcare Conference on November 11, 2025 in New York, and one-on-one meetings at the Jefferies London Healthcare Conference on November 17–19, 2025 in London.

The company is a clinical-stage biotechnology firm developing multifunctional biotherapeutics for oncology, inflammation, and autoimmune diseases; these investor meetings are opportunities to discuss clinical progress and corporate strategy with investors and analysts.

Zymeworks (NASDAQ: ZYME) reported preliminary Phase 1 clinical data for ZW191, an antibody-drug conjugate targeting folate receptor-α, presented Oct 23, 2025. As of Sep 10, 2025, 41 patients were enrolled (doses 1.6–11.2 mg/kg) with 85% remaining on treatment.

Key efficacy: among response-evaluable patients (n=27) overall ORR 44%; at 6.4–9.6 mg/kg ORR 53%. In gynecological cancers (n=24) ORR was 50% overall and 64% at 6.4–9.6 mg/kg. Responses began at 3.2 mg/kg and occurred with low/negative FRα expression.

Safety and next steps: no serious treatment-related AEs, discontinuations for AEs, or deaths reported. Common Grade ≥3 treatment-related AEs: anemia 10%, neutropenia 5%, thrombocytopenia 5%. MTD determined at 11.2 mg/kg; dose-optimization cohorts at 6.4 mg/kg and 9.6 mg/kg planned (~30 patients each) with dose optimization to start in 4Q-2025.

Zymeworks (Nasdaq: ZYME) will report third quarter 2025 financial results after market close on November 6, 2025. Management will host a conference call and live webcast the same day at 4:30 pm Eastern Time to discuss results and provide a corporate update.

Dial-in details and webcast replays will be available on Zymeworks’ investor website at https://ir.zymeworks.com/events-and-presentations.

Zymeworks (Nasdaq: ZYME) will present preliminary Phase 1 clinical data for ZW191, an antibody-drug conjugate targeting folate receptor-α using payload ZD06519, at the AACR-NCI-EORTC conference in Boston on October 23, 2025.

The poster covers first-in-human, multicenter, open-label Part 1 results in patients with advanced solid tumors including ovarian, endometrial, and non-small cell lung cancer. A live webcast and investor call with lead author Patricia LoRusso, DO, PhD (hc), FAACR and Zymeworks management will occur on October 23, 2025 at 3:30 pm ET. Dial-in and replay are available on Zymeworks' investor site.